The estimated Net Worth of Lauren Riker is at least $1.77 Millón dollars as of 12 June 2024. Ms Riker owns over 3,970 units of Pacira BioSciences Inc stock worth over $494,975 and over the last 12 years she sold PCRX stock worth over $1,277,921.
Ms has made over 35 trades of the Pacira BioSciences Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently she sold 3,970 units of PCRX stock worth $114,018 on 12 June 2024.
The largest trade she's ever made was exercising 10,000 units of Pacira BioSciences Inc stock on 14 March 2013 worth over $103,400. On average, Ms trades about 2,145 units every 89 days since 2012. As of 12 June 2024 she still owns at least 38,075 units of Pacira BioSciences Inc stock.
You can see the complete history of Ms Riker stock trades at the bottom of the page.
Lauren Bullaro Riker is the Principal Accounting Officer & VP of Fin. at Pacira BioSciences Inc.
Ms Riker is 42, she's been the Principal Accounting Officer & VP of Fin. of Pacira BioSciences Inc since . There are 25 older and no younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
Lauren's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon y Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: